Glenmark Pharma’s Next Big Move: Launching 8.4% Sodium Bicarbonate Injection in the US Market
Glenmark Pharmaceuticals is creating waves in the global pharma market again! The US subsidiary of the company, which is Glenmark Pharmaceuticals Inc., USA, has announced the upcoming launch of its 8.4% Sodium Bicarbonate Injection USP (50mEq/50mL, 1mEq/mL), which is used crucially in hospitals in the US Market.
It’s not just the launch of another product; the drug has been certified as bioequivalent and therapeutically equivalent to Abbott Laboratories’ product, meaning it has the same quality and effectiveness as Abbott’s product. This shows Glenmark’s mission to deliver affordable and high-quality injections to patients across the world.
Glenmark’s Presence In the US Injectable Market
The 8.4% Sodium Bicarbonate Injection is more often used in emergency care to treat conditions such as Metabolic acidosis, which is said to occur when there’s too much production of acid in the body. With the introduction of this trusted product in the US market, Glenmark can broaden its injectables profile, which can help the company to focus on its long-term growth.
According to the sales data of IQVIA, the US market for this particular injection product is worth $63.8 million in the 12-month period ending August 2025. The entry of Glenmark Pharma into this space could help it gain a significant position in the market, supplying a cost-effective alternative to healthcare providers and hospitals.
Marc Kikuchi, the president & business head of Glenmark in North America, commented, “We are pleased to announce the expansion of our injectable profile with the launch of 8.4% sodium bicarbonate injection USP. This shows our dedication to bringing quality and affordable alternatives to patients in need”.
While Glenmark continues to expand its company globally, it has faced some losses in the last quarter of the year. The company has reported a 23.4% drop in net profit to Rs. 260.79 Crore, alongside a 5.1% dip in revenue to Rs. 3,059.33 crore in Q1 FY26 compared to the same period last year.
This US launch is going to play a key role in reviving the growth and its reputation in the global pharma markets.
With the upcoming launch of 8.4% Sodium Bicarbonate injection, Glenmark Pharma is not just expanding its product line but strengthening its competitive position in the US pharma market. It’s the move that shows the company’s motive to make life-saving medicines more available and affordable to patients globally.
